Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   32951   clinical trials with a EudraCT protocol, of which   5327   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2014-001703-41
    Sponsor's Protocol Code Number:WTX101-201
    National Competent Authority:Germany - BfArM
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2014-06-05
    Trial results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - BfArM
    A.2EudraCT number2014-001703-41
    A.3Full title of the trial
    A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older with an Extension Phase of 36 Months
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A clinical trial in adult Wilson Disease Patients to evaluate efficacy and safety of WTX101 following administration for 24 weeks and an extension phase of 36 months.
    A.4.1Sponsor's protocol code numberWTX101-201
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorWilson Therapeutics AB
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportWilson Therapeutics AB
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationWilson Therapeutics
    B.5.2Functional name of contact pointSusan Flint
    B.5.3 Address:
    B.5.3.1Street Address 7 Swanson Lane
    B.5.3.2Town/ cityWestford
    B.5.3.3Post codeMA 01886
    B.5.3.4CountryUnited States
    B.5.4Telephone number+16175133787
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU3/12/1089
    D.3 Description of the IMP
    D.3.2Product code WTX101
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNnone
    D.3.9.1CAS number 64-9749-10-0
    D.3.9.2Current sponsor codeWTX101
    D.3.9.3Other descriptive namebis-choline TETRATHIOMOLYBDATE
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number15
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Wilson Disease
    E.1.1.1Medical condition in easily understood language
    Wilson Disease
    E.1.1.2Therapeutic area Body processes [G] - Metabolic Phenomena [G03]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.1
    E.1.2Level LLT
    E.1.2Classification code 10047988
    E.1.2Term Wilson's disease
    E.1.2System Organ Class 100000004850
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective is to evaluate the efficacy of WTX101 for 24 weeks on non-ceruloplasmin-bound copper (NCC) levels adjusted for molybdenum (Mo) plasma concentration in newly diagnosed Wilson Disease (WD) patients aged 18 and older with NCC levels within or above the normal reference range at the time of enrolment.
    E.2.2Secondary objectives of the trial
    - Establish the safety and tolerability of individualised dosing of WTX101 over the course of the study period
    - Evaluate: change in and time to normalisation of NCC levels adjusted for Mo plasma concentration; the effects of WTX101 on neurological status using the UWDRS (neurological subscore; parts I, II and III); the effects of WTX101 on psychiatric status using M.I.N.I. Tracking; the global effects of WTX101 on clinical symptoms as assessed by the Investigators on the CGI scale items 1 (severity of illness) and 2 (global improvement); the effects of WTX101 on the following QoL / PRO endpoint measures: EQ5D, MAQ-8 and the TSQM, the effects of WTX101 on hepatic measures
    - Analyse copper endpoints (exchangeable copper, speciation profiling, and 24-hour urinary copper)
    - Collect PK data on WTX101 in this patient population based on the measurement of plasma total Mo
    - Evaluate the durability, and establish long-term safety and efficacy of WTX101 in a 36 month Extension Phase
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Willing and able to give informed consent for participation in the study.
    Male or female patients, aged 18 years or older as of signing the ICF.
    Able to understand and willing to comply with study procedures, restrictions and requirements, as judged by the Investigator.
    Newly established diagnosis of Wilson Disease by Leipzig-Score >/=4 (Ferenci et al 2003) documented by testing as outlined in 2012 EASL WD Clinical Practice Guidelines.
    NCC levels above or within the normal reference range (0.8-2.3 µM).
    Willing to undergo 48 hour washout from current Wilson Disease treatment.
    E.4Principal exclusion criteria
    Treatment for greater than 24 months for Wilson Disease with chelation therapy (i.e. penicillamine, trientine hydrochloride) or zinc therapy.
    Decompensated hepatic cirrhosis.
    Model for End-Stage Liver Disease (MELD) score > 11.
    Modified Nazer score > 6 (Dhawan et al. Liver Transplant 2005).
    GI bleed within past 6 months.
    ALT > 5x upper limit of normal (ULN).
    Marked neurological disease requiring either nasogastric (NG) feeding or intensive in-patient medical care.
    Severe anaemia with a haemoglobin < 9 g/dL.
    E.5 End points
    E.5.1Primary end point(s)
    Non-ceruloplasmin-bound copper (NCC) levels adjusted for molybdenum (Mo) plasma concentration
    E.5.1.1Timepoint(s) of evaluation of this end point
    24 weeks
    E.5.2Secondary end point(s)
    - Change in NCC levels adjusted for Mo plasma concentration
    - Time to normalisation of NCC adjusted for Mo plasma concentration
    - Change in exchangeable copper during 24 weeks of treatment
    - Change in speciation profiling (Mo, Cu and protein complex profiling with SEC) during 24 weeks of treatment
    - Change in 24-hour urinary copper during 24 weeks of treatment
    - Changes in hepatic measures (ALT, AST, INR and bilirubin)
    - Changes in neurological status using the UWDRS (neurological subscore; parts I, II and III) and additionally:
    - Number of patients that deteriorate = increase ≥ 4 (part III of neurological sub-score) or increase ≥ 1 (part II of neurological sub-score).
    - Number of patients that improve = decrease ≥ 4 (part III of neurological sub-score) or decrease ≥ 1 (part II of neurological sub-score).
    - Changes in psychiatric status using M.I.N.I. Tracking
    - Changes in the global effects of WTX101 on clinical symptoms assessed by the Investigators on the CGI scale items 1 (severity of illness) and 2 (global improvement)
    - Absolute changes in QOL / PRO measures EQ5D, MAQ-8, TSQM
    - Pharmacokinetic (PK) data based on measurement of plasma total molybdenum (Mo)
    - Durability and long term efficacy of WTX101 in a 36 month Extension Phase.
    E.5.2.1Timepoint(s) of evaluation of this end point
    24 weeks, variable
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA8
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months4
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 29
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 1
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state5
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 15
    F.4.2.2In the whole clinical trial 30
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients are offered the opportunity to participate in the 36 month extension phase to evaluate the durability, and establish long-term safety and efficacy of WTX101 or are assisted in their transition to standard of care for WD under the guidance of their local physician.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-08-18
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-08-12
    P. End of Trial
    P.End of Trial StatusOngoing
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-Tue Jul 17 10:51:06 BST 2018 | 30 Churchill Place, Canary Wharf, London E14 5EU
    Legal notice